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Sequencing of theMycobacterium tuberculosis pncA gene allows for pyrazinamide susceptibility testing. We summarize data on
pncA polymorphisms that do not confer resistance at a susceptibility breakpoint of 100g/ml pyrazinamide inMGIT within a
cohort of isolates from South Africa and the U.S. Centers for Disease Control and Prevention.
Culture-based drug susceptibility testing (DST) using BactecMGIT 960 PZA medium (Becton Dickinson, Sparks, MD) at
100 g/ml is the current gold standard test for pyrazinamide
(PZA) resistance (1). False resistance results are known to occur
with this assay (1, 2), which may be the result of alkalinization of
the medium due to a high inoculum size or the presence of bovine
serum albumin (3). The uses of alternative susceptibility break-
point concentrations or different media are additional factors that
may contribute to disparities in PZA susceptibility results (4–6). A
further limitation of culture-based methods is the long turn-
around time, which can exceed 20 days (7–9). Molecular methods
offer an alternative strategy for the detection of PZA susceptibility.
These methods detect polymorphisms in the 561-bp pncA gene,
which encodes the pyrazinamidase (PZase) enzyme that is respon-
sible for conversion of PZA (prodrug) to pyrazinoic acid (active
form) (10). More than 325 polymorphisms (single nucleotide
polymorphisms [SNPs], insertions, and deletions) throughout the
length of the pncA gene and in the promoter region have been
described, complicating molecular detection (11–14). A good cor-
relation (sensitivity of 90%) between pncA polymorphisms in
circulating isolates and phenotypic susceptibility results have been
observed for PZA (15–18). Incomplete correlation of pncAmolec-
ular results with culture-based PZA testing has been ascribed to
poor reproducibility of the phenotypic test or the presence of al-
ternative genetic mechanisms for resistance, including polymor-
phisms in the rpsA gene (19, 20). Additionally, a few pncA muta-
tions have been reported in the absence of phenotypic resistance
(15), but the role of such mutations in PZA resistance has not been
thoroughly investigated. This study aimed to collate data on pncA
polymorphisms in clinical isolates that do not confer resistance at
a susceptibility breakpoint of 100g/ml PZA. To capture the spec-
trum of pncA mutations not associated with phenotypic PZA re-
sistance, we performed a comprehensive literature search. In the
77 papers reporting genotypic and phenotypic PZA susceptibility
(see Table S1 in the supplemental material), 77 different pncA
polymorphisms in 71 different codons were reported to have a
PZA-susceptible phenotype using either Bactec MGIT 960 PZA
(Becton Dickinson, Sparks, MD), Bactec 460 PZA (Becton Dick-
inson, Sparks, MD) or the Wayne assay (21). Forty-seven (61%) of
these polymorphisms have also been reported in PZA-resistant
isolates. These inconsistent phenotypic results may be due to tech-
nical difficulties of phenotypic PZA assays or MICs that are close
to the breakpoint. Another 26 (33.7%) mutations were found in
only one or two isolates, suggesting that these new mutations need
to be characterized further to determine their role in PZA resis-
tance.
To further investigate the relationship between pncA mutation
and PZA susceptibility, we analyzed clinical isolates from culture
collections at the Centers for Disease Control and Prevention
(CDC), Atlanta, GA, USA (n 185) and Stellenbosch University,
Stellenbosch, South Africa (SA) (n 865). For the CDC isolates,
pncA was previously sequenced, and only isolates with mutant
pncA were included in this study. For the SA isolates, the pncA
gene was amplified and sequenced using the ABI3130XL genetic
analyzer (Applied Biosystems, Foster City, CA, USA). Polymor-
phisms in pncA were identified in 231 (26.7%) of the SA clinical
isolates relative to those in the PZA-susceptible H37Rv reference
strain. All isolates harboring pncA mutations (CDC and SA) were
subjected to DST against PZA (BD PZA kit) at a critical concen-
tration of 100 g/ml using Bactec 960 MGIT. This phenotypic
testing identified 7 of 185 (3.8%) CDC isolates and 42 of 231
(18.2%) SA isolates to have a susceptible PZA phenotype despite
the presence of mutant pncA alleles. These results were confirmed
by repeat pncA sequencing and repeat PZA DST. From these 49
isolates, 10 different pncA polymorphisms (synonymous, n  2;
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nonsynonymous, n  8) were identified (Table 1). Six polymor-
phisms were newly identified in this study, while 4 corresponded
to previously described pncA polymorphisms. Of these four, only
Thr114Met was previously observed exclusively in susceptible iso-
lates. The polymorphisms were not restricted to a defined domain
but were broadly distributed throughout the pncA gene, with a
distribution similar to that of resistance-causing mutations (22).
To further explore PZA resistance, each of the 49 PZA-suscep-
tible isolates identified in this study was subjected to PZA MIC
determination using PZA concentrations of 25, 50, 75, and 100
g/ml in Bactec MGIT 960 PZA medium. Six of the polymor-
phisms (all nonsynonymous SNPs) showed MICs between 50 and
100 g/ml, 3 polymorphisms (2 were synonymous) were asso-
ciated with MICs of25 g/ml, and 1 polymorphism had MICs
of25 for one isolate and50 for a second isolate (Table 1). It is
important to note that most of the pncA polymorphisms associ-
ated with susceptible isolates (7/10) identified in this study had a
PZA MIC between 50 and 100 g/ml. Six of 10 pncA polymor-
phisms associated with susceptibility were present in more than
one isolate. The reproducibility of the MIC determinations across
different clinical isolates with the same pncA mutation supports
the notion that these polymorphisms do not confer resistance
above the breakpoint concentration. However, some of the SNPs
identified in this study were reported to confer resistance in other
studies (see Table S1 in the supplemental material, references 1, 2,
24, 36, 50, 76). These conflicting results may be due to the PZA
MICs for these isolates being close to breakpoint or associated
with technical difficulties of performing PZA DST on solid media
(1, 2).
We acknowledge that the clinical relevance of these polymor-
phisms on treatment outcome remain to be determined. In a re-
cent report, an MIC of 50 g/ml and 100 g/ml was associ-
ated with a poor 2 month sputum conversion (relative risk of 1.5
[95% confidence interval, 1.2 to 1.8]) compared with that of an
MIC of50g/ml (23). Accordingly, the authors concluded that
a PZA susceptibility breakpoint of50 g/ml should be used for
clinical decision making. However, one cannot exclude other fac-
tors that may have contributed to the observed delayed treatment
response (23).
Based on the current accepted PZA susceptibility breakpoint
concentration of 100 g/ml (1), not all pncA mutations necessar-
ily confer resistance. We propose that genetic PZA drug suscepti-
bility testing results should be interpreted based on known phe-
notype and genotype relationships at a susceptibility breakpoint
of 100 g/ml until further evidence is presented to support any
revision of the susceptibility breakpoint. Further studies are re-
quired to improve our understanding of the relationship between
treatment outcome and pncA mutations.
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